Gianluca Vago

  • Presidente Fondazione CNAO, former rector University of Milan

Prof. Gianluca Vago has held the position of President of the National Center for Oncological Hadrontherapy (CNAO) of Pavia since January 2019, after serving on the Board of Directors from 2013 to 2018.

He holds a degree in Medicine and Surgery and a specialization in Anatomy and Pathological Histology, and he is Full Professor of Pathological Anatomy at the University of Milan. He has covered several academic roles at the same university, serving as Rector from 2012 to 2018 and as Director of the Department of Oncology and Hemato-Oncology since 2021. He was President of the Council of the International Degree Course in Medicine and Surgery from 2011 to 2012 and directs the School of Specialization in Pathological Anatomy. Furthermore, he held the position of President of the Coordinating Committee of the Lombard Universities from 2013 to 2018, and since 2025, he has served as President of the Lombard Life Sciences Cluster (Cluster Lombardo Scienze della Vita).

He directed the Operational Unit of Pathological Anatomy of the L. Sacco Hospital in Milan from 2003 to 2011, and the Department of Diagnostic Services of the same hospital from 2010. From February 2012 to October of the same year, he directed the Department of Diagnostic Services at the Humanitas Clinical Institute in Milan.

He was a member of the Human Technopole Commission for the drafting of the Foundation’s Statute.

He is the author of 155 scientific publications. His early research focused on the pathology and diagnosis of infectious diseases — with particular reference to HIV-related disorders of the central nervous system — and on experimental models in the field of immunology. More recently, his research has expanded significantly into the fields of oncology and advanced medical technologies, with a strong focus on the integration of artificial intelligence and computational pathology into diagnostics, augmented reality in surgery, and the role of carbon-ion therapy in oncological hadron therapy.